Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
The first patent submission covers the Company's innovative Interferon-gamma (IFNγ) Biosensor, a technology that enables real-time monitoring and quantification of IFNγ release from cytokine-secreting cells.
- The first patent submission covers the Company's innovative Interferon-gamma (IFNγ) Biosensor, a technology that enables real-time monitoring and quantification of IFNγ release from cytokine-secreting cells.
- Additionally, Medigene has filed two patents for its novel T cell receptor (TCR)-specific Antigen-Antibody combination technology, UniTope & TraCR.
- “These innovative tools enable Medigene to increase the overall efficiency for the development of potential best-in-class TCRs and TCR-based therapies.
- Medigene continually extends and strengthens its patent portfolio with new technologies and expands existing patents into additional jurisdictions.